View in EDS

Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.

Saved in:
Bibliographic Details
Title: Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
Authors: Heinrich K; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; Comprehensive Cancer Center, University Hospital (LMU), Munich, Germany. Electronic address: kathrin.heinrich@med.uni-muenchen.de., Stintzing S; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT) Berlin, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Weikersthal LFV; Gesundheitszentrum St. Marien, Amberg, Germany., Decker T; Onkologie Ravensburg, Ravensburg, Germany., Kiani A; Department of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, and Comprehensive Cancer Center Erlangen EMN, Erlangen, Germany., Kaiser F; Oncological Practice, Landshut, Germany., Al-Batran SE; Institute of Clinical Cancer Research at Krankenhaus Nordwest University Cancer Center, Frankfurt, Germany., Heintges T; Department of Medicine II, Städtische Kliniken Neuss, Neuss, Germany., Lerchenmüller C; Oncological Practice, Münster, Germany., Kahl C; Department of Haematology and Oncology, Städtisches Klinikum Magdeburg, Magdeburg, Germany., Seipelt G; Oncological Practice, Bad Soden, Germany., Kullmann F; Department of Medicine I, Klinikum Weiden, Weiden, Germany., Moehler M; Department of Medicine II, University Hospital, Johannes Gutenberg University Mainz, Mainz, Germany., Scheithauer W; Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Jung A; Institute of Pathology, University of Munich, Munich, Germany., Holch JW; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; Comprehensive Cancer Center, University Hospital (LMU), Munich, Germany., Held S; AIO-Studien-gGmbH, Germany., Modest DP; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT) Berlin, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Heinemann V; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; Comprehensive Cancer Center, University Hospital (LMU), Munich, Germany.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2026 Jan; Vol. 232, pp. 116133. Date of Electronic Publication: 2025 Nov 22.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41319450
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Heinrich+K%22">Heinrich K</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; Comprehensive Cancer Center, University Hospital (LMU), Munich, Germany. Electronic address: kathrin.heinrich@med.uni-muenchen.de.<br /><searchLink fieldCode="AU" term="%22Stintzing+S%22">Stintzing S</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT) Berlin, German Cancer Research Centre (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Weikersthal+LFV%22">Weikersthal LFV</searchLink>; Gesundheitszentrum St. Marien, Amberg, Germany.<br /><searchLink fieldCode="AU" term="%22Decker+T%22">Decker T</searchLink>; Onkologie Ravensburg, Ravensburg, Germany.<br /><searchLink fieldCode="AU" term="%22Kiani+A%22">Kiani A</searchLink>; Department of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, and Comprehensive Cancer Center Erlangen EMN, Erlangen, Germany.<br /><searchLink fieldCode="AU" term="%22Kaiser+F%22">Kaiser F</searchLink>; Oncological Practice, Landshut, Germany.<br /><searchLink fieldCode="AU" term="%22Al-Batran+SE%22">Al-Batran SE</searchLink>; Institute of Clinical Cancer Research at Krankenhaus Nordwest University Cancer Center, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Heintges+T%22">Heintges T</searchLink>; Department of Medicine II, Städtische Kliniken Neuss, Neuss, Germany.<br /><searchLink fieldCode="AU" term="%22Lerchenmüller+C%22">Lerchenmüller C</searchLink>; Oncological Practice, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Kahl+C%22">Kahl C</searchLink>; Department of Haematology and Oncology, Städtisches Klinikum Magdeburg, Magdeburg, Germany.<br /><searchLink fieldCode="AU" term="%22Seipelt+G%22">Seipelt G</searchLink>; Oncological Practice, Bad Soden, Germany.<br /><searchLink fieldCode="AU" term="%22Kullmann+F%22">Kullmann F</searchLink>; Department of Medicine I, Klinikum Weiden, Weiden, Germany.<br /><searchLink fieldCode="AU" term="%22Moehler+M%22">Moehler M</searchLink>; Department of Medicine II, University Hospital, Johannes Gutenberg University Mainz, Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Scheithauer+W%22">Scheithauer W</searchLink>; Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Jung+A%22">Jung A</searchLink>; Institute of Pathology, University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Holch+JW%22">Holch JW</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; Comprehensive Cancer Center, University Hospital (LMU), Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Held+S%22">Held S</searchLink>; AIO-Studien-gGmbH, Germany.<br /><searchLink fieldCode="AU" term="%22Modest+DP%22">Modest DP</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT) Berlin, German Cancer Research Centre (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Heinemann+V%22">Heinemann V</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; Comprehensive Cancer Center, University Hospital (LMU), Munich, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229005373%22">European journal of cancer (Oxford, England : 1990)</searchLink> [Eur J Cancer] 2026 Jan; Vol. 232, pp. 116133. <i>Date of Electronic Publication: </i>2025 Nov 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Ltd%22">Elsevier Science Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9005373 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-0852 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209598049%22">09598049 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41319450
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ejca.2025.116133
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 116133
    Titles:
      – TitleFull: Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Heinrich K
      – PersonEntity:
          Name:
            NameFull: Stintzing S
      – PersonEntity:
          Name:
            NameFull: Weikersthal LFV
      – PersonEntity:
          Name:
            NameFull: Decker T
      – PersonEntity:
          Name:
            NameFull: Kiani A
      – PersonEntity:
          Name:
            NameFull: Kaiser F
      – PersonEntity:
          Name:
            NameFull: Al-Batran SE
      – PersonEntity:
          Name:
            NameFull: Heintges T
      – PersonEntity:
          Name:
            NameFull: Lerchenmüller C
      – PersonEntity:
          Name:
            NameFull: Kahl C
      – PersonEntity:
          Name:
            NameFull: Seipelt G
      – PersonEntity:
          Name:
            NameFull: Kullmann F
      – PersonEntity:
          Name:
            NameFull: Moehler M
      – PersonEntity:
          Name:
            NameFull: Scheithauer W
      – PersonEntity:
          Name:
            NameFull: Jung A
      – PersonEntity:
          Name:
            NameFull: Holch JW
      – PersonEntity:
          Name:
            NameFull: Held S
      – PersonEntity:
          Name:
            NameFull: Modest DP
      – PersonEntity:
          Name:
            NameFull: Heinemann V
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2026 Jan
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1879-0852
          Numbering:
            – Type: volume
              Value: 232
          Titles:
            – TitleFull: European journal of cancer (Oxford, England : 1990)
              Type: main
ResultId 1